Neurological autoimmunity targeting aquaporin-4

Neuroscience

Volumn 168, Issue 4, 2010, Pages 1009-1018

  Hinson, S R ^a   McKeon, A ^a   Lennon, V A ^a,b  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

Multiple sclerosis; Neuromyelitis optica; NMO IgG

Indexed keywords

AQUAPORIN 4; AUTOANTIBODY; AUTOANTIGEN; AZATHIOPRINE; BETA INTERFERON; COMPLEMENT; CORTICOSTEROID; EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLASMA PROTEIN; RITUXIMAB; IMMUNOGLOBULIN G;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BLOOD BRAIN BARRIER; CELL MEDIATED CYTOTOXICITY; CLINICAL FEATURE; COMPLEMENT ACTIVATION; DEMYELINATING DISEASE; DISEASE COURSE; DISEASE MARKER; DOWN REGULATION; DRUG MEGADOSE; EDEMA; GRANULOCYTE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INFLAMMATORY CELL; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PHENOTYPE; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RECURRENT DISEASE; REVIEW; TREATMENT RESPONSE; ANIMAL; BRAIN; IMMUNOLOGY; METABOLISM;

ANIMALS; AQUAPORIN 4; AUTOIMMUNITY; BRAIN; HUMANS; IMMUNOGLOBULIN G; NEUROMYELITIS OPTICA;

EID: 77953687243     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2009.08.032     Document Type: Review

References (71)

1. Antoine J.C., Camdessanche J.P., Absi L., Lassabliere F., Feasson L. Devic disease and thymoma with anti-central nervous system and antithymus antibodies. Neurology 2004, 62:978-980.
2. Bakker J., Metz L. Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 2004, 31:265-267.
3. Barger S.W., Goodwin M.E., Porter M.M., Beggs M.L. Glutamate release from activated microglia requires the oxidative burst and lipid peroxidation. J Neurochem 2007, 101:1205-1213.
4. Benarroch E.E. Neuronal microenvironment. Basic neuroscience with clinical applications 2006, Butterworth-Heinneman, Philadelphia, PA. E.E. Bennarroch (Ed.).
5. Cornell-Bell A.H., Thomas P.G., Smith S.J. The excitatory neurotransmitter glutamate causes filopodia formation in cultured hippocampal astrocytes. Glia 1990, 3:322-334.
6. Dehouck M.P., Meresse S., Delorme P., Fruchart J.C., Cecchelli R. An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro. J Neurochem 1990, 54:1798-1801.
7. Devic E. Myélite aiguë compliquée de névrite optique. Bull Med 1894, 8:1033-1034.
8. Doi H., Matsushita T., Isobe N., Matsuoka T., Minohara M., Ochi H., Kira J.I. Hypercomplementemia at relapse in patients with anti-aquaporin-4 antibody. Mult Scler 2009, 15:304-310.
9. Domercq M., Sanchez-Gomez M.V., Sherwin C., Etxebarria E., Fern R., Matute C. System xc- and glutamate transporter inhibition mediates microglial toxicity to oligodendrocytes. J Immunol 2007, 178:6549-6556.
10. Ducray F., Roos-Weil R., Garcia P.Y., Slesari J., Heinzlef O., Chatelain D., Toussaint P., Roullet E., Honnorat J. Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2007, 78:325-327.
11. Engel A., Fujiyoshi Y., Gonen T., Walz T. Junction-forming aquaporins. Curr Opin Struct Biol 2008, 18:229-235.
12. Falcini F., Trapani S., Ricci L., Resti M., Simonini G., de Martino M. Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment. Rheumatology (Oxford, England) 2006, 45:913-915.
13. Fink K., Lang K.S., Manjarrez-Orduno N., Junt T., Senn B.M., Holdener M., Akira S., Zinkernagel R.M., Hengartner H. Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses. Eur J Immunol 2006, 36:2094-2105.
14. Frigeri A., Gropper M.A., Turck C.W., Verkman A.S. Immunolocalization of the mercurial-insensitive water channel and glycerol intrinsic protein in epithelial cell plasma membranes. Proc Natl Acad Sci U S A 1995, 92:4328-4331.
15. Frigeri A., Gropper M.A., Umenishi F., Kawashima M., Brown D., Verkman A.S. Localization of MIWC and GLIP water channel homologs in neuromuscular, epithelial and glandular tissues. J Cell Sci 1995, 108:2993-3002.
16. Gault F (1894) (De la neuromyelité optique aiguë. Thèse de Lyon serre 1.).
17. Hinson SR, McKeon A, Fryer JP, Apiwattanakul M, Lennon VA, Pittock SJ (in press) Complement-mediated injury to AQP4-expressing cells may predict attack severity in neuromyelitis optica. Arch Neurol, in press.
18. Hinson S.R., Pittock S.J., Lucchinetti C.F., Roemer S.F., Fryer J.P., Kryzer T.J., Lennon V.A. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007, 69:2221-2231.
19. Hinson S.R., Roemer S.F., Lucchinetti C.F., Fryer J.P., Kryzer T.J., Chamberlain J.L., Howe C.L., Pittock S.J., Lennon V.A. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 2008, 205:2473-2481.
20. Hiroaki Y., Tani K., Kamegawa A., Gyobu N., Nishikawa K., Suzuki H., Walz T., Sasaki S., Mitsuoka K., Kimura K., Mizoguchi A., Fujiyoshi Y. Implications of the aquaporin-4 structure on array formation and cell adhesion. J Mol Biol 2006, 355:628-639.
21. Hirrlinger J., Hulsmann S., Kirchhoff F. Astroglial processes show spontaneous motility at active synaptic terminals in situ. Eur J Neurosci 2004, 20:2235-2239.
22. Jacob A., Weinshenker B.G., Matiello M., Wingerchuk D.M., Carter J., Kantarci O., Keegan B.M., Shuster E., Lucchinetti C.F., Pittock S.J. Treatment of neuromyelitis optica with mycophenolate: retrospective analysis of 25 cases. Mult Scler 2007, 13:S244.
23. Jacob A., Weinshenker B.G., Violich I., McLinskey N., Krupp L., Fox R.J., Wingerchuk D.M., Boggild M., Constantinescu C.S., Miller A., De Angelis T., Matiello M., Cree B.A. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008, 65:1443-1448.
24. Kantarci O.H., Weinshenker B.G. Natural history of multiple sclerosis. Neurol Clin 2005, 23:17-38. v.
25. Keegan M., Pineda A.A., McClelland R.L., Darby C.H., Rodriguez M., Weinshenker B.G. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002, 58:143-146.
26. Lachance D.L., Lennon V.A. Paraneoplastic neurological autoimmunity. Neuroimmunology in clinical practice 2008, 210-217. Blackwell Publishing. B. Kalman, T.H. Brannagan (Eds.).
27. Lennon V.A., Kryzer T.J., Pittock S.J., Verkman A.S., Hinson S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473-477.
28. Lennon V.A., Lindstrom J.M., Seybold M.E. Experimental autoimmune myasthenia: a model of myasthenia gravis in rats and guinea pigs. J Exp Med 1975, 141:1365-1375.
29. Lennon V.A., Lucchinetti C.F., Weinshenker B.G. Identification of a marker autoantibody of neuromyelitis optica. Neurology 2003, 60:A519-A520.
30. Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., Nakashima I., Weinshenker B.G. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106-2112.
31. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47:707-717.
32. Lucchinetti C.F., Mandler R.N., McGavern D., Bruck W., Gleich G., Ransohoff R.M., Trebst C., Weinshenker B., Wingerchuk D., Parisi J.E., Lassmann H. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125:1450-1461.
33. Mandler R.N., Ahmed W., Dencoff J.E. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998, 51:1219-1220.
34. Mattson M.P. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromol Med 2003, 3:65-94.
35. McCoy E., Sontheimer H. Expression and function of water channels (aquaporins) in migrating malignant astrocytes. Glia 2007, 55:1034-1043.
36. McDonald J.W., Althomsons S.P., Hyrc K.L., Choi D.W., Goldberg M.P. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nat Med 1998, 4:291-297.
37. McKeon A, Fryer JP, Lennon VA, Apiwattanakul M, Hinson SR, Kryzer TJ, Lucchinetti CF, Weinshenker BG, Wingerchuk DM, Shuster EA, Pittock SJ (in press) Diagnosis of neuromyelitis spectrum disorders: comparative sensitivities and specificities of immunohistochemical and immunoprecipitation assays. Arch Neurol, in press.
38. McKeon A., Lennon V.A., Jacob A., Matiello M., Lucchinetti C.F., Kale N., Chan K.H., Weinshenker B.G., Apiwattinakul M., Wingerchuk D.M., Pittock S.J. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 2009, 39:87-90.
39. McKeon A., Lennon V.A., Lotze T., Tenenbaum S., Ness J.M., Rensel M., Kuntz N.L., Fryer J.P., Homburger H., Hunter J., Weinshenker B.G., Krecke K., Lucchinetti C.F., Pittock S.J. CNS aquaporin-4 autoimmunity in children. Neurology 2008, 71:93-100.
40. Misu T., Fujihara K., Kakita A., Konno H., Nakamura M., Watanabe S., Takahashi T., Nakashima I., Takahashi H., Itoyama Y. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007, 130:1224-1234.
41. Misu T., Fujihara K., Nakashima I., Sato S., Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology 2005, 65:1479-1482.
42. Morgan B.P., Gasque P. Expression of complement in the brain: role in health and disease. Immunol Today 1996, 17:461-466.
43. Nielsen S., Nagelhus E.A., Amiry-Moghaddam M., Bourque C., Agre P., Ottersen O.P. Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci 1997, 17:171-180.
44. Park E., Velumian A.A., Fehlings M.G. The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for white matter degeneration. J Neurotrauma 2004, 21:754-774.
45. Piani D., Fontana A. Involvement of the cystine transport system xc-in the macrophage-induced glutamate-dependent cytotoxicity to neurons. J Immunol 1994, 152:3578-3585.
46. Pittock S.J., Lennon V.A. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol 2008, 65:629-632.
47. Pittock S.J., Lennon V.A., de Seze J., Vermersch P., Homburger H.A., Wingerchuk D.M., Lucchinetti C.F., Zephir H., Moder K., Weinshenker B.G. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008, 65:78-83.
48. Pittock S.J., Lennon V.A., Krecke K., Wingerchuk D.M., Lucchinetti C.F., Weinshenker B.G. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006, 63:390-396.
49. Pittock S.J., Weinshenker B.G., Lucchinetti C.F., Wingerchuk D.M., Corboy J.R., Lennon V.A. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006, 63:964-968.
50. Pittock S.J., Weinshenker B.G., Wingerchuk D.M., Lucchinetti C.F., Lennon V.A. Autoimmune neurological accompaniments of neuromyelitis optica (NMO). Ann Neurol 2006, 60:S41.
51. Ramagopalan S.V., Dyment D.A., Valdar W., Herrera B.M., Criscuoli M., Yee I.M., Sadovnick A.D., Ebers G.C. Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol 2007, 6:604-610.
52. Rash J.E., Davidson K.G., Yasumura T., Furman C.S. Freeze-fracture and immunogold analysis of aquaporin-4 (AQP4) square arrays, with models of AQP4 lattice assembly. Neuroscience 2004, 129:915-934.
53. Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005, 353:1711-1723.
54. Ridet J.L., Malhotra S.K., Privat A., Gage F.H. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci 1997, 20:570-577.
55. Roemer S.F., Parisi J.E., Lennon V.A., Benarroch E.E., Lassmann H., Bruck W., Mandler R.N., Weinshenker B.G., Pittock S.J., Wingerchuk D.M., Lucchinetti C.F. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007, 130:1194-1205.
56. Spiller O.B., Moretto G., Kim S.U., Morgan B.P., Devine D.V. Complement expression on astrocytes and astrocytoma cell lines: failure of complement regulation at the C3 level correlates with very low CD55 expression. J Neuroimmunol 1996, 71:97-106.
57. Takahashi T., Fujihara K., Nakashima I., Misu T., Miyazawa I., Nakamura M., Watanabe S., Ishii N., Itoyama Y. Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J Exp Med 2006, 210:307-313.
58. Vallejo-Illarramendi A., Domercq M., Perez-Cerda F., Ravid R., Matute C. Increased expression and function of glutamate transporters in multiple sclerosis. Neurobiol Dis 2006, 21:154-164.
59. Verkhratsky A., Orkand R.K., Kettenmann H. Glial calcium: homeostasis and signaling function. Physiol Rev 1998, 78:99-141.
60. Vincent T., Saikali P., Cayrol R., Roth A.D., Bar-Or A., Prat A., Antel J.P. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol 2008, 181:5730-5737.
61. Warabi Y., Matsumoto Y., Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 2007, 252:57-61.
62. Waters P., Jarius S., Littleton E., Leite M.I., Jacob S., Gray B., Geraldes R., Vale T., Jacob A., Palace J., Maxwell S., Beeson D., Vincent A. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008, 65:913-919.
63. Weinshenker B.G., Wingerchuk D.M., Lucchinetti C.F., Lennon V.A. A marker autoantibody discriminates neuromyelitis optica from multiple sclerosis. Neurology 2003, 60:A520.
64. Weinshenker B.G., Wingerchuk D.M., Vukusic S., Linbo L., Pittock S.J., Lucchinetti C.F., Lennon V.A. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006, 59:566-569.
65. Wingerchuk D.M., Hogancamp W.F., O'Brien P.C., Weinshenker B.G. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999, 53:1107-1114.
66. Wingerchuk D.M., Lennon V.A., Lucchinetti C.F., Pittock S.J., Weinshenker B.G. The spectrum of neuromyelitis optica. Lancet Neurol 2007, 6:805-815.
67. Wingerchuk D.M., Lennon V.A., Pittock S.J., Lucchinetti C.F., Weinshenker B.G. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485-1489.
68. Wingerchuk D.M., Pittock S.J., Lucchinetti C.F., Lennon V.A., Weinshenker B.G. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007, 68:603-605.
69. Yang C., Jones J.L., Barnum S.R. Expression of decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 in the human astroglioma cell line, D54-MG, and primary rat astrocytes. J Neuroimmunol 1993, 47:123-132.
70. Yang Y., Gozen O., Watkins A., Lorenzini I., Lepore A., Gao Y., Vidensky S., Brennan J., Poulsen D., Won Park J., Li Jeon N., Robinson M.B., Rothstein J.D. Presynaptic regulation of astroglial excitatory neurotransmitter transporter GLT1. Neuron 2009, 61:880-894.
71. Yu Z., Lennon V.A. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999, 340:227-228.